Small study measures early bacteria-killing power of azithromycin for MAC lung disease
NCT ID NCT04287049
First seen Nov 17, 2025 · Last updated May 15, 2026 · Updated 19 times
Summary
This pilot study looked at how well the antibiotic azithromycin kills Mycobacterium avium complex (MAC) bacteria in the lungs during the first 14 days of treatment. Ten adults with MAC lung disease provided sputum samples to measure bacterial levels. The goal was to understand early drug activity, not to cure or control the disease long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM AVIUM COMPLEX are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21205, United States
Conditions
Explore the condition pages connected to this study.